Exelixis | EXEL - PE Price to Earnings


Exelixis reported 18.43 in PE Price to Earnings for its fiscal quarter ending in September of 2026.





Pe Change Date
Acadia Pharmaceuticals 9.52 1.81 Sep/2026
Agios Pharmaceuticals 3.56 0 Mar/2026
Akebia Therapeutics 1.63K 1.6K Dec/2025
Amgen 18.6 0.53 Sep/2026
AstraZeneca 24.63 0.71 Sep/2026
Bayer 4.61 0.47 Sep/2026
BioMarin Pharmaceutical 53.62 32.55 Sep/2026
Bristol-Myers Squibb 10.44 5.7 Sep/2026
Eisai 30.24 3.68 Sep/2026
Eli Lilly 64.5 31.61 Sep/2026
Exelixis 18.43 0.41 Sep/2026
Genmab 16.04 1.05 Jun/2026
Glaxosmithkline 15.17 0.08 Sep/2026
Incyte 54.54 40.08 Sep/2026
Ionis Pharmaceuticals 396.15 79.28 Sep/2022
Merck 34.36 2.11 Sep/2026
Moderna 27.22 14.51 Jun/2023
Neurocrine Biosciences 83.17 61.07 Sep/2026
Novartis 19.17 3.24 Sep/2026
Pfizer 15.2 3.72 Sep/2026
Puma Biotechnology 13.93 44.88 Jun/2024
Sanofi 21.74 11.35 Sep/2026
Takeda 21.04 3.36 Sep/2026
Xencor 29.92 3.22 Sep/2022